I thank all members who have stayed behind tonight to support this motion and all those members who signed my motion. For those who have not yet signed the motion, I of course always welcome sinners who repent.
On the surface, the debate may seem to be a surrogate for another round of Brexit speeches plus a seminar on an arcane institution—Euratom—or a poor man’s lecture on nuclear physics. However, I am sorry if any member is here under false pretences. The issue is very simple: the future treatment and care of cancer patients and the security of supply of radioisotopes.
Notwithstanding my opening statement, I will attempt to set the context of the problem. The United Kingdom joined the European Atomic Energy Community, which is better known as Euratom, on 1 January 1973. The UK gave notice to leave Euratom as part of the article 50 process, and the European Commission is clear that
“the Euratom Treaty will cease to apply to the UK on 30 March 2019”.
Why is that a problem for health services and cancer patients? Euratom is a crucial and essential vehicle for the management of radioisotopes. As the Euratom Supply Agency mission statement makes clear, its job is to support
“secure and safe supply and use of medical radioisotopes.”
Members will be aware that medical radioisotopes are used in radiotherapy for treatment of cancer and in nuclear medicine for both diagnostic work and therapy. The principal radioisotope used worldwide is technetium, which is derived from a parent element that has a half-life of 66 hours. The element is obtained from a small number of research nuclear reactors, none of which is located in the UK. The Hinkley Point nuclear research facility, which is planned for 2027, could produce medical isotopes, but the jury is out as to when that facility will be completed. The bulk of the UK’s supply is from the European Union and is facilitated by the Euratom supply operation. For example, the High Flux reactor in the Netherlands supplies the UK and has capacity for a third of global demand. However, it is estimated that it will cease operations in 2024.
Therefore, the context is that we have a world shortage of medical isotopes. A key provider, Canada, has just ceased production, so the EU is home to four of the top six global producers. The distances to Australia and South Africa, which are also significant players, mean that they are problematic providers, because supply would be limited by the decay of medical isotopes during transportation.
The key issue is that isotopes have short half-lives, which means that they decay rapidly and cannot be stored. That creates an urgent need for a constant, reliable and predictable supply, but that has failed in the past and created global shortages. Euratom has a central and crucial leadership role, because it supervises the supply chains. There was a crisis in 2008, with the closure of the Channel tunnel, and a crisis again in 2015, when industrial action in Calais caused chaos in the transportation of isotopes and the cancellation of treatment across the UK.
I argue today that there is a clear and present danger to the national health service in Scotland and beyond. The loss of frictionless borders post-Brexit could result in a traumatic failure to deliver medical isotopes on time to cancer patients. As the Royal College of Radiologists has said,
“Navigating Brexit is undoubtedly a huge task for ministers, but our access to these vital materials for diagnosing and treating cancer must not be left to slip down the negotiations list.”
Radioisotopes are essential tools for nuclear medicine that combine with a drug that guides isotopes to a particular part of the body. The scale of use is immense and invaluable. In the UK, about 700,000 nuclear medicine procedures are carried out each year, of which around 70,000 are in Scotland. They are essential in diagnosing coronary disease, detecting the spread of cancer to the bones and biomedical research. As the British Nuclear Medicine Society has said,
“patients will be poorly served by not having a cheap, plentiful supply of”
technetium, which is the most commonly used medical isotope.
What are our options? On a simplistic level, if it ain’t broke, why fix it? We could stay in Euratom. However, with the current UK Administration that decision is unlikely.
Secondly, we could look at having associate status of Euratom under article 206 of the Euratom treaty, which sets that out with reciprocal rights and special procedures. The best example is Switzerland, which joined in 2014. That status gives access to funding for nuclear research.
Thirdly, we could join the USA, Australia and Canada in having third-country status under article 101 of the treaty. The advantage of that is that we would have common research on a shared-cost basis.
I apologise for the technology, but we could create more cyclotrons in Scotland. That is not from a recent episode of “Dr Who”; a cyclotron is a linear accelerator that produces radioisotopes for positron emission tomography and computerised tomography scanners, better known as PET and CT scanners. There are three in Scotland—in Glasgow, Edinburgh and Aberdeen—but there is no spare capacity for the PET scanner in Dundee. While I am on my feet, I must campaign for a PET scanner in the Highlands, which spends £300,000 on scans alone. However, in my view, a large-scale switch is expensive and probably unlikely.
Fifthly, what about waiting for Hinkley Point C to be up and running in 2027? As I said earlier, the big question is whether it will be on time. Further, what will its capacity be? We still need to organise the supply chain management.
During the debates in the House of Commons on the European Union (Withdrawal) Bill, many MPs made telling contributions saying that, if we withdraw from the club—the Euratom Supply Agency—during a global shortage of medical isotopes, why should the club care for us? As the old saying from Capitol Hill goes, if you are not at the table, you are on the menu.
One does not need the predictive powers of the Brahan seer—who, incidentally, in the 17th century, predicted the second world war—to divine the future in this area. We have a global shortage of radioisotopes; we produce none of our own; and we are leaving the market that produces the majority of the world’s supply. This is not an obscure academic debate but something that will influence the quality and quantity of life for cancer patients in the UK now and in the future. As Jimmy Dean once said,
“I can’t change the direction of the wind but I can adjust my sails to always reach my destination.”
17:16